QNCX
Quince Therapeutics, Inc.
NASDAQ: QNCX · HEALTHCARE · BIOTECHNOLOGY
$22.00
+13.58% today
Updated 2026-07-29
Market cap
$18.26M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-210.00
Dividend yield
—
52W range
$15 – $910
Volume
0.9M
WallStSmart proprietary scores
23
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C5.5
Quality
C+3.0
Profitability
D5.0
Valuation
C+1/9
Piotroski F-Score
Weak
-10.0
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →206 stocks currently score above 75
Price targets
Analyst target
$83.33
+278.77%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy3 Buy3 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Debt/equity 0.03x — low leverage
Risks
- Piotroski 1/9 — weak financial health
- Altman Z -10.00 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-7.63M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-51.66M | $-31.39M | $-56.83M | $-83.98M | $35.91M |
| EPS | — | — | — | — | $-210.00 |
| Free cash flow | $-44.17M | $-18.45M | $-32.16M | $-41.78M | $-7.63M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Quince Therapeutics, Inc. trades at $22.00. Our Smart Value Score of 23/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -10.00, it sits in the distress.
Frequently asked questions
What is Quince Therapeutics, Inc.'s stock price?
Quince Therapeutics, Inc. (QNCX) trades at $22.00.
Is Quince Therapeutics, Inc. overvalued?
Quince Therapeutics, Inc. carries a Smart Value Score of 23/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Quince Therapeutics, Inc. (QNCX)?
The 12-month analyst consensus target is $83.33, about 278.8% above the current $22.00. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Quince Therapeutics, Inc.'s Altman Z-Score is -10.00, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-210.80%
Beta1.40
50D MA$20.45
200D MA$233.58
Shares out0.00B
Float0.00B
Short ratio—
Avg volume0.9M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—